Submission Details
| 510(k) Number | K250588 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | February 27, 2025 |
| Decision Date | November 17, 2025 |
| Days to Decision | 263 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
K250588 is an FDA 510(k) clearance for the Access Rubella IgG, a Enzyme Linked Immunoabsorbent Assay, Rubella (Class II — Special Controls, product code LFX), submitted by Beckman Coulter, Inc. (Chaska, US). The FDA issued a Cleared decision on November 17, 2025, 263 days after receiving the submission on February 27, 2025. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3510.
| 510(k) Number | K250588 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | February 27, 2025 |
| Decision Date | November 17, 2025 |
| Days to Decision | 263 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
| Product Code | LFX — Enzyme Linked Immunoabsorbent Assay, Rubella |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.3510 |